Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP Sells $177,050.78 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) SVP William E. Rote sold 8,951 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $19.78, for a total value of $177,050.78. Following the completion of the sale, the senior vice president now owns 95,719 shares of the company’s stock, valued at approximately $1,893,321.82. This represents a 8.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Travere Therapeutics Stock Performance

Shares of NASDAQ TVTX traded up $0.88 during trading on Tuesday, reaching $21.10. 987,233 shares of the stock traded hands, compared to its average volume of 1,250,242. The company has a 50-day moving average of $18.69 and a 200-day moving average of $15.47. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $21.56. The stock has a market capitalization of $1.65 billion, a P/E ratio of -4.64 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in Travere Therapeutics in the 4th quarter worth about $53,000. CWM LLC grew its holdings in shares of Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares in the last quarter. Quarry LP bought a new position in shares of Travere Therapeutics in the third quarter worth approximately $105,000. Baader Bank Aktiengesellschaft purchased a new stake in Travere Therapeutics in the fourth quarter valued at approximately $192,000. Finally, Diversified Trust Co bought a new stake in Travere Therapeutics during the third quarter valued at approximately $161,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on TVTX shares. Wedbush upped their target price on Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $9.00 to $27.00 in a research note on Monday, October 21st. Guggenheim raised their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Bank of America lifted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Leerink Partners reissued an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, October 8th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.